{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:41:06Z","timestamp":1790959266347,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clgc.2022.08.009","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T02:29:22Z","timestamp":1661740162000},"page":"568-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes"],"prefix":"10.1016","volume":"20","author":[{"given":"Matthew","family":"Mossanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9105","authenticated-orcid":false,"given":"Amin H.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Martinez-Chanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-5651","authenticated-orcid":false,"given":"Vivek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-8079","authenticated-orcid":false,"given":"Pier Vitale","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-5219","authenticated-orcid":false,"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-3982","authenticated-orcid":false,"given":"Judy E.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dory","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7343","authenticated-orcid":false,"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-7781","authenticated-orcid":false,"given":"Adam","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-9611","authenticated-orcid":false,"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma Q.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.08.009_bib0001","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"6","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0002","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0003","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0022-5347(17)59540-3","article-title":"Familial transitional cell carcinoma of the bladder","volume":"113","author":"McCullough","year":"1975","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0004","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0022-5347(17)56461-7","article-title":"Familial factors in bladder carcinoma","volume":"122","author":"Lynch","year":"1979","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cncr.22071","article-title":"Bladder cancer risk as modified by family history and smoking","volume":"107","author":"Lin","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.08.009_bib0006","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.urolonc.2008.02.016","article-title":"Familial and genetic risk of transitional cell carcinoma of the urinary tract","volume":"26","author":"Mueller","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0007","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic Countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2022.08.009_bib0008","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.19.01395","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies","volume":"38","author":"Carlo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0009","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41436-019-0720-x","article-title":"Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma","volume":"22","author":"Nassar","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.clgc.2022.08.009_bib0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jmg.2010.076992","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"van der Post","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.clgc.2022.08.009_bib0011","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.urology.2015.08.018","article-title":"Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations","volume":"86","author":"Joost","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2022.08.009_bib0012","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2022.08.009_bib0013","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eururo.2012.07.047","article-title":"Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer","volume":"63","author":"Skeldon","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0014","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2022.08.009_bib0015","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1053\/j.gastro.2009.08.052","article-title":"Expanded extracolonic tumor spectrum in MUTYH-associated polyposis","volume":"137","author":"Vogt","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clgc.2022.08.009_bib0016","article-title":"Inherited germline cancer susceptibility gene variants in individuals with non-muscle-invasive bladder cancer","volume":"14","author":"Pietzak","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.08.009_bib0017","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.299.20.2423","article-title":"Genetic susceptibility to cancer: the role of polymorphisms in candidate genes","volume":"299","author":"Dong","year":"2008","journal-title":"Jama"},{"key":"10.1016\/j.clgc.2022.08.009_bib0018","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.1967.03130070027006","article-title":"Malignant bladder tumors in a man and his three sons","volume":"201","author":"Fraumeni","year":"1967","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2022.08.009_bib0019","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/BLC-170159","article-title":"Bladder cancer genetic susceptibility. A systematic review","volume":"4","author":"de Maturana","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.clgc.2022.08.009_bib0020","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1055-9965.EPI-06-0743","article-title":"Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?","volume":"16","author":"Murta-Nascimento","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clgc.2022.08.009_bib0021","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ijc.2910350602","article-title":"Familial and environmental interactions in bladder cancer risk","volume":"35","author":"Kantor","year":"1985","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2022.08.009_bib0022","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","article-title":"Germline variants in targeted tumor sequencing using matched normal DNA","volume":"2","author":"Schrader","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0023","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2022.08.009_bib0024","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0025","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic implications of germline testing in patients with advanced cancers","volume":"39","author":"Stadler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.436","article-title":"A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma","author":"Crabb","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.08.009_bib0027","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.437","article-title":"Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: a multicenter, randomized, phase II trial (BAYOU)","author":"Rosenberg","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732200177X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732200177X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:11Z","timestamp":1761564971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732200177X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S155876732200177X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.08.009","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}